Loading…
← CockpitCompetitor Analysis › 300434.SZ Sichuan Goldstone Asia Pharmaceutical, Inc. Class AOpen in the cockpit ↗

Sichuan Goldstone Asia Pharmaceutical, Inc. Class A300434.SZCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Manufacturing
Momentum strong 68
Mkt cap
$639M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$53.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.1 pp
WACC 9.0%
Hurdle
+3 pp
Req g minus delivered
Close · CNYCN¥10.80
1D-3.1%
1W-16.6%
1M-11.8%
3M-16.0%
6M-6.1%
YTD+5.1%
1Y-4.8%
ATR %7.0%
52w lowhigh25.1% off high

What Sichuan Goldstone Asia Pharmaceutical does

Employees: 1,794

Sichuan Goldstone Asia Pharmaceutical at a glance

Size Sichuan Goldstone Asia Pharmaceutical (300434.SZ) is a China Industrials company (Miscellaneous Manufacturing) with a market value of $639M, the 3097th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.80 on 18 Nov 2026.

Performance Over six months the shares fell 6.1%, against -25.0% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 1.3% over the last twelve months (peer median +5.2%); the operating margin is 17.9% (peer median 1.4%).

Valuation It trades at 3.6× enterprise value to sales against a peer median of 2.3× (6th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.1 points below its cost of capital (9.0% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026300434.SZ 95Peer median 75
Six months, rebased to 100: Sichuan Goldstone Asia Pharmaceutical against the median of its 20 peers (local-currency closes).

Sichuan Goldstone Asia Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.04BCN¥1.03BCN¥1.09BCN¥1.20BCN¥1.23B
Revenue growth—-6%-9%-3%—
Gross profitCN¥676MCN¥540MCN¥566MCN¥683MCN¥705M
EBITDAn/aCN¥242MCN¥231MCN¥341MCN¥368M
Net incomeCN¥176MCN¥132MCN¥91.8MCN¥126MCN¥219M
Free cash flowCN¥162MCN¥109MCN¥87.0MCN¥86.0MCN¥271M
Capital expenditureCN¥97.3MCN¥99.6MCN¥72.9MCN¥66.1MCN¥54.1M
Total debtCN¥112MCN¥125MCN¥144MCN¥175MCN¥93.0M

Quarterly statements and history in the cockpit →

Sichuan Goldstone Asia Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%301003603657300587002632603370001356688151301397300389600525RHIM300868300232300234002403300991300599603311002382002676300434.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Sichuan Goldstone Asia Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%2×4×6×301003603657300587002632603370001356688151301397300389600525RHIM300868300232300234002403300991300599603311002382002676300434.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sichuan Goldstone Asia Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%301003002632688151300389600525RHIM300232002403002382002676300434.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sichuan Goldstone Asia Pharmaceutical is the large dot.

Sichuan Goldstone Asia Pharmaceutical competitors and peer comparison

How Sichuan Goldstone Asia Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sichuan Goldstone Asia Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300434.SZPeer medianRank in peer set
1-month return-11.8%-11.1%11th highest of 21
6-month return-6.1%-25.0%5th highest of 21
Distance from 52-week high-25.1%-45.2%4th highest of 21
Revenue growth (TTM)-1.3%+5.2%5th lowest of 21
Operating margin17.9%1.4%2nd highest of 21
EV / Sales3.6×2.3×6th most expensive of 21
Growth the price implies (Req g, 7 yrs)9.2%5.8%5th most demanding of 11
Growth delivered (Del g)+6.2%+4.3%5th highest of 11
Hurdle (Req g minus delivered)+3.0 pp-0.0 pp4th most demanding of 11
ROIC minus cost of capital-0.1 pp-6.4 pp8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sichuan Goldstone Asia Pharmaceutical 300434.SZChina$639M-6%-1%18%3.6×9.2%+6.2%
Jiangsu Boiln Plastics 301003.SZChina$646M-19%+7%20%6.0×19.9%+3.6%
Jinhua Chunguang Technology 603657.SSChina$662M+13%+22%-4%1.7×n/an/a
Zhejiang Tiantie Science & Technology 300587.SZChina$665M-46%+24%-4%3.2×n/an/a
Daoming Optics & Chemical 002632.SZChina$676M-33%-10%12%3.0×5.8%+3.3%
Jiangyin Huaxin Precision Technology 603370.SSChina$584M-52%+11%7%2.3×n/an/a
Fuling Technology 001356.SZChina$704M-33%+17%6%2.0×n/an/a
Hubei Huaqiang High-Tech 688151.SSChina$718M-29%+13%-5%2.9×41.6%-5.6%
Chongqing Sulian Plastic 301397.SZChina$552M-40%+3%2%2.4×n/an/a
Shenzhen Absen Optoelectronic 300389.SZChina$543M-26%+13%8%0.8×-2.6%+20.4%
Changyuan Technology 600525.SSChina$760M-24%+7%-7%0.9×-12.9%+5.1%
RHI Magnesita India RHIM.NSIndia$763M-10%+4%8%1.8×25.2%+24.1%
Shenzhen Jame Technology 300868.SZChina$764M-56%+8%-7%7.0×n/an/a
Unilumin 300232.SZChina$772M-23%+1%0%0.7×5.9%+10.3%
Zhejiang Kaier New Materials 300234.SZChina$774M+43%-17%-9%17.4×n/an/a
Aishida 002403.SZChina$522M-3%+1%-9%1.8×51.3%-1.5%
Shenzhen Chuangyitong Technology 300991.SZChina$520M-49%-10%-1%5.8×n/an/a
Guangdong Xiongsu Technology 300599.SZChina$519M-19%-15%-16%3.5×n/an/a
Zhejiang Goldensea Hi-Tech 603311.SSChina$791M-3%+3%7%5.6×n/an/a
Blue Sail Medical 002382.SZChina$801M-21%+23%7%1.2×-7.2%-6.1%
Guangdong Sunwill Precising Plastic 002676.SZChina$504M-30%+1%4%1.6×5.6%+10.9%

Questions

Which companies are Sichuan Goldstone Asia Pharmaceutical's closest peers?
The cockpit's peer set: Jiangsu Boiln Plastics (301003.SZ), Jinhua Chunguang Technology (603657.SS), Zhejiang Tiantie Science & Technology (300587.SZ), Daoming Optics & Chemical (002632.SZ), Jiangyin Huaxin Precision Technology (603370.SS), Fuling Technology (001356.SZ), Hubei Huaqiang High-Tech (688151.SS), Chongqing Sulian Plastic (301397.SZ).
Is Sichuan Goldstone Asia Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.6× against a peer median of 2.3×, 6th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sichuan Goldstone Asia Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -6.1% against -25.0% for the median peer; over one year -4.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.